TY - JOUR
T1 - A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma
AU - Cloud, M. L.
AU - Enas, G. C.
AU - Kemp, J.
AU - Platts-Mills, T.
AU - Altman, L. C.
AU - Townley, R.
AU - Tinkelman, D.
AU - King, T.
AU - Middleton, E.
AU - Sheffer, A. L.
AU - McFadden, E. R.
AU - Farlow, D. S.
PY - 1989/1/1
Y1 - 1989/1/1
N2 - LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15% increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.
AB - LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15% increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.
UR - http://www.scopus.com/inward/record.url?scp=0024474179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024474179&partnerID=8YFLogxK
U2 - 10.1164/ajrccm/140.5.1336
DO - 10.1164/ajrccm/140.5.1336
M3 - Article
C2 - 2554766
AN - SCOPUS:0024474179
VL - 140
SP - 1336
EP - 1339
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
SN - 1073-449X
IS - 5
ER -